Structure-based classification predicts drug response in EGFR-mutant NSCLC
2021 · Nature · 427 citations
https://doi.org/10.1038/s41586-021-03898-1
J
Junqin He
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
64
Papers
2.1K
Citations
20
h-index
22
i10-index
Junqin He is an academic researcher from The University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & CAR-T cell therapy research & Immune Cell Function and Interaction. The author has an h-index of 20, co-authored 55 publications.
ORCID: 0009-0001-1406-0544Papers by this author
worksRole of the endothelin axis in astrocyte- and endothelial cell-mediated chemoprotection of cancer cells
2014 · Neuro-Oncology · 100 citations
https://doi.org/10.1093/neuonc/nou128
Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations
2020 · Journal of Thoracic Oncology · 72 citations
https://doi.org/10.1016/j.jtho.2020.05.021
Macitentan (ACT-064992), a Tissue-Targeting Endothelin Receptor Antagonist, Enhances Therapeutic Efficacy of Paclitaxel by Modulating Survival Pathways in Orthotopic Models of Metastatic Human Ovarian Cancer
2011 · Neoplasia · 46 citations
https://doi.org/10.1593/neo.10806
Antivascular Therapy for Multidrug-Resistant Ovarian Tumors by Macitentan, a Dual Endothelin Receptor Antagonist
2012 · Translational Oncology · 31 citations
https://doi.org/10.1593/tlo.11286
HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies
2023 · Journal of Thoracic Oncology · 17 citations
https://doi.org/10.1016/j.jtho.2023.08.034
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat